Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

KRAS (Kirsten Rat Sarcoma) Mutant CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Locally Advanced and Metastatic PANcreatic Cancer

NCT04560270 is registered in ClinicalTrials.gov with Poitiers University Hospital as lead sponsor.

NCT NCT04560270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04560270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
KRAS (Kirsten Rat Sarcoma) Mutant CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Locally Advanced and Metastatic PANcreatic Cancer
Lead sponsor
Poitiers University Hospital
Phase
Not applicable
Overall status
Completed
Start date
April 25, 2016
Completion date
November 15, 2019
Enrollment
69 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

circulating tumor dna, kras mutation-related tumors, pancreatic cancer